UroGen Pharma Ltd (URGN)
13.30
-0.25
(-1.84%)
USD |
NASDAQ |
May 31, 16:00
13.31
+0.01
(+0.08%)
After-Hours: 20:00
UroGen Pharma Enterprise Value: 414.08M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 414.08M |
| May 30, 2024 | 423.11M |
| May 29, 2024 | 412.63M |
| May 28, 2024 | 425.28M |
| May 24, 2024 | 411.91M |
| May 23, 2024 | 397.82M |
| May 22, 2024 | 414.44M |
| May 21, 2024 | 412.99M |
| May 20, 2024 | 399.98M |
| May 17, 2024 | 411.18M |
| May 16, 2024 | 410.82M |
| May 15, 2024 | 431.42M |
| May 14, 2024 | 402.15M |
| May 13, 2024 | 405.77M |
| May 10, 2024 | 393.84M |
| May 09, 2024 | 402.15M |
| May 08, 2024 | 412.99M |
| May 07, 2024 | 419.49M |
| May 06, 2024 | 433.95M |
| May 03, 2024 | 450.21M |
| May 02, 2024 | 448.76M |
| May 01, 2024 | 453.82M |
| April 30, 2024 | 432.86M |
| April 29, 2024 | 440.81M |
| April 26, 2024 | 444.79M |
| Date | Value |
|---|---|
| April 25, 2024 | 432.86M |
| April 24, 2024 | 446.95M |
| April 23, 2024 | 458.52M |
| April 22, 2024 | 452.73M |
| April 19, 2024 | 429.58M |
| April 18, 2024 | 448.73M |
| April 17, 2024 | 448.00M |
| April 16, 2024 | 457.04M |
| April 15, 2024 | 479.07M |
| April 12, 2024 | 479.07M |
| April 11, 2024 | 412.24M |
| April 10, 2024 | 401.40M |
| April 09, 2024 | 416.57M |
| April 08, 2024 | 410.79M |
| April 05, 2024 | 424.88M |
| April 04, 2024 | 426.33M |
| April 03, 2024 | 427.05M |
| April 02, 2024 | 442.58M |
| April 01, 2024 | 446.56M |
| March 31, 2024 | 475.46M |
| March 28, 2024 | 473.41M |
| March 27, 2024 | 472.05M |
| March 26, 2024 | 479.22M |
| March 25, 2024 | 530.06M |
| March 22, 2024 | 499.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
45.06M
Minimum
Feb 24 2022
748.47M
Maximum
Aug 14 2023
322.59M
Average
319.75M
Median
Enterprise Value Benchmarks
| Agenus Inc | 301.30M |
| Exelixis Inc | 5.355B |
| Geron Corp | 1.745B |
| Protalix BioTherapeutics Inc | 54.78M |
| InfuSystems Holdings Inc | 181.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.29M |
| Revenue (Quarterly) | 18.78M |
| Total Expenses (Quarterly) | 44.52M |
| EPS Diluted (Quarterly) | -0.97 |
| Gross Profit Margin (Quarterly) | 90.80% |
| Profit Margin (Quarterly) | -171.9% |
| Earnings Yield | -25.11% |
| Normalized Earnings Yield | -20.82 |